Quick Answer
Cellebrite DI Ltd. reported Total Revenue of $475.68 million for fiscal year 2025.
Cellebrite DI Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $475.68M +18.6% |
$401.20M +23.4% |
$325.11M +20.1% |
$270.65M +9.9% |
$246.25M +26.3% |
$194.91M +13.4% |
| Revenue (ASC 606) | $475.68M +18.6% |
$401.20M +23.4% |
$325.11M +20.1% |
$270.65M +9.9% |
$246.25M +26.3% |
$194.91M +13.4% |
| Net Income | $78.33M +127.7% |
-$283.01M -249.0% |
-$81.10M -167.1% |
$120.81M +69.2% |
$71.40M +1135.0% |
$5.78M +408.2% |
| Diluted EPS | $0.31 +123.0% |
-$1.35 -214.0% |
-$0.43 -172.9% |
$0.59 +34.1% |
$0.44 +650.0% |
-$0.08 +0.0% |
| Total Assets | $938.85M +36.0% |
$690.57M +29.6% |
$532.88M +32.1% |
$403.29M +18.7% |
$339.78M -6.8% |
$364.39M |
| Cash and Equivalents | $124.46M -35.1% |
$191.66M +1.1% |
$189.52M +116.2% |
$87.64M | — | — |
| Stockholders Equity | $484.32M +44.1% |
$336.02M +882.2% |
$34.21M -53.7% |
$73.86M +200.7% |
-$73.35M -215.0% |
$63.80M +8.5% |
| R&D Expense | $113.88M +15.7% |
$98.42M +16.6% |
$84.39M +4.7% |
$80.62M +23.0% |
$65.54M +20.5% |
$54.38M +16.8% |
| Operating Income | $66.48M +16.8% |
$56.91M +71.2% |
$33.24M +3083.6% |
$1.04M -92.4% |
$13.82M +49.9% |
$9.22M +706.4% |
| Gross Profit | $400.50M +18.3% |
$338.61M +24.5% |
$271.88M +23.6% |
$219.91M +8.0% |
$203.69M +29.7% |
$157.03M +15.4% |
| Shares Outstanding | 248.58M +6.0% |
234.52M +15.4% |
203.23M +5.3% |
193.01M +2.8% |
187.68M +50.5% |
124.67M |
- Cellebrite DI Ltd. reported Total Revenue of $475.68 million for fiscal year 2025.
- Cellebrite DI Ltd. showed an increase of +18.6% in Total Revenue compared to the prior fiscal year.
- Cellebrite DI Ltd. reported Revenue (ASC 606) of $475.68 million for fiscal year 2025.
- Cellebrite DI Ltd. showed an increase of +18.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Cellebrite DI Ltd. reported Net Income of $78.33 million for fiscal year 2025.
- Cellebrite DI Ltd. showed an increase of +127.7% in Net Income compared to the prior fiscal year.
- Cellebrite DI Ltd. reported Diluted EPS of $0.31 per share for fiscal year 2025.
- Cellebrite DI Ltd. showed an increase of +123.0% in Diluted EPS compared to the prior fiscal year.
- Cellebrite DI Ltd. reported Total Assets of $938.85 million for fiscal year 2025.
- Cellebrite DI Ltd. showed an increase of +36.0% in Total Assets compared to the prior fiscal year.
- Cellebrite DI Ltd. reported Cash and Equivalents of $124.46 million for fiscal year 2025.
- Cellebrite DI Ltd. showed a decrease of -35.1% in Cash and Equivalents compared to the prior fiscal year.
- Cellebrite DI Ltd. reported Stockholders Equity of $484.32 million for fiscal year 2025.
- Cellebrite DI Ltd. showed an increase of +44.1% in Stockholders Equity compared to the prior fiscal year.
- Cellebrite DI Ltd. reported R&D Expense of $113.88 million for fiscal year 2025.
- Cellebrite DI Ltd. showed an increase of +15.7% in R&D Expense compared to the prior fiscal year.
- Cellebrite DI Ltd. reported Operating Income of $66.48 million for fiscal year 2025.
- Cellebrite DI Ltd. showed an increase of +16.8% in Operating Income compared to the prior fiscal year.
- Cellebrite DI Ltd. reported Gross Profit of $400.50 million for fiscal year 2025.
- Cellebrite DI Ltd. showed an increase of +18.3% in Gross Profit compared to the prior fiscal year.
- Cellebrite DI Ltd. reported Shares Outstanding of 248.58 million shares for fiscal year 2025.
- Cellebrite DI Ltd. showed an increase of +6.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: